Alpha-1-Adrenergic receptors (ARs) are catecholamine-activated G protein-coupled receptors (GPCRs) that are expressed in mouse and human myocardium and vasculature and play essential roles in the regulation of cardiovascular physiology. Though alpha-1-ARs are less abundant in the heart than beta-1-ARs, activation of cardiac alpha-1 ARs results in important biologic processes such as hypertrophy, positive inotropy, ischemic preconditioning and protection from cell death. Data from the ALLHAT trial indicate that non-selectively blocking alpha-1-ARs is associated with a two-fold increase in adverse cardiac events including heart failure and angina, suggesting that alpha-1-AR activation might also be cardioprotective in humans. Mounting evidence implicates the alpha-1A-AR subtype in these adaptive effects, including prevention and reversal of heart failure in animal models by a1A agonists. In this minireview, we summarize recent advances in our understanding of cardiac alpha-1A-ARs.

中文翻译：

---

心脏 α-1A-肾上腺素能受体：在心血管疾病中的新兴保护作用

Alpha-1-肾上腺素受体 (ARs) 是儿茶​​酚胺激活的 G 蛋白偶联受体 (GPCRs)，在小鼠和人类心肌和脉管系统中表达，在心血管生理调节中起重要作用。尽管 alpha-1-ARs 在心脏中的含量不如 beta-1-ARs，但心脏 alpha-1 ARs 的激活会导致重要的生物学过程，例如肥大、正性肌力、缺血预处理和防止细胞死亡。ALLHAT 试验的数据表明，非选择性阻断 alpha-1-AR 与包括心力衰竭和心绞痛在内的心脏不良事件增加两倍相关，这表明 alpha-1-AR 激活也可能对人类有心脏保护作用。越来越多的证据表明 alpha-1A-AR 亚型与这些适应性效应有关，包括通过 a1A 激动剂预防和逆转动物模型中的心力衰竭。在这篇综述中，我们总结了我们对心脏 alpha-1A-ARs 理解的最新进展。